RGD Reference Report - Pentraxin-3 as a marker of disease severity and risk of death in patients with necrotizing soft tissue infections: a nationwide, prospective, observational study. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Pentraxin-3 as a marker of disease severity and risk of death in patients with necrotizing soft tissue infections: a nationwide, prospective, observational study.

Authors: Hansen, Marco Bo  Rasmussen, Lars Simon  Garred, Peter  Bidstrup, Daniel  Madsen, Martin Bruun  Hyldegaard, Ole 
Citation: Hansen MB, etal., Crit Care. 2016 Feb 15;20:40. doi: 10.1186/s13054-016-1210-z.
RGD ID: 38508899
Pubmed: PMID:26880104   (View Abstract at PubMed)
PMCID: PMC4754810   (View Article at PubMed Central)
DOI: DOI:10.1186/s13054-016-1210-z   (Journal Full-text)


BACKGROUND: New biomarkers are needed to assess the severity of necrotizing soft tissue infection (NSTI) at an early stage and to individualize treatment strategies. We assessed pentraxin-3 (PTX3) as a marker of disease severity and risk of death in patients with NSTI.
METHODS: We conducted a prospective, observational study in the intensive care unit at Copenhagen University Hospital, where treatment of NSTI is centralized at a national level. We compared PTX3, procalcitonin and C-reactive protein in septic shock versus nonshock patients and in amputated versus nonamputated patients using the Mann-Whitney U test. The prognostic value of the markers for 180-day mortality was assessed using Cox regression analyses.
RESULTS: Patients with NSTI (n = 135) were included over 25 months with up to 2.5-year follow-up; 71% had septic shock, amputation was undertaken in 20% and the 180-day mortality was 27%. Baseline plasma PTX3 level was significantly higher in patients with septic shock (67.3 versus 24.6 ng/mL, p < 0.0001) and in patients who underwent amputation (118.6 versus 43.6 ng/mL, p = 0.019). No significant differences in baseline procalcitonin or C-reactive protein levels were found according to amputation (25.2 versus 7.0 μg/L, p = 0.060 and 202 versus 225 mg/L, p = 0.123), respectively. Baseline PTX3 level above the median was associated with death (p = 0.009, log-rank test) and the univariate Cox regression analysis revealed a significant association between PTX3 level upon admission and 180-day mortality (hazard ratio 2.60 (95% confidence interval 1.28-5.29), p = 0.008). When adjusted for age, sex, chronic disease and Simplified Acute Physiology Score II, no significant association was found.
CONCLUSIONS: High PTX3 level is associated with septic shock, amputation and risk of death in patients with NSTI, but it is not an independent predictor of 180-day mortality in this patient group.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02180906. Date of registration: June 29, 2014.

RGD Manual Disease Annotations    Click to see Annotation Detail View
TermQualifierEvidenceWithReferenceNotesSourceOriginal Reference(s)
necrotizing soft tissue infection severityIEP 38508899protein:decreased expression:plasma (human)RGD 
necrotizing soft tissue infection severityISOPTX3 (Homo sapiens)38508899; 38508899protein:decreased expression:plasma (human)RGD 

Objects Annotated

Genes (Rattus norvegicus)
Ptx3  (pentraxin 3)

Genes (Mus musculus)
Ptx3  (pentraxin related gene)

Genes (Homo sapiens)
PTX3  (pentraxin 3)


Additional Information